For COVID-19 and vaccination updates, view our information for the community. If you're experiencing symptoms, call your primary care provider.

Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

GOG-3035/OncoQuest QPT-ORE-005/FLORA-5

Trial Overview

Official Title

A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Clinical Study comparing Chemo-Immunotherapy (Paclitaxel – Carboplatin - Oregovomab) versus Chemotherapy (Paclitaxel-Carboplatin-Placebo) In Patients with Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Study Purpose

To see how safe and effective four doses of the experimental drug oregovomab is given at the same time as specific cycles of the chemotherapy regimen paclitaxel and carboplatin.

Diagnosis

Patients with newly diagnosed epithelial adenocarcinoma of ovarian, fallopian tube or peritoneal origin FIGO Stage III or IV disease.

Eligibility

Newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal cancer.

BRCA negative.

Completed debulking surgery (both primary and interval allowed).

ECOG 0-1. No mucinous or low-grade adeno allowed.

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Intervention

Adjuvant chemo (3 or 6 cycles depending on primary or interval debulking) + Oregovomab/Placebo

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Gender
Female
Age
19 years and older
Enrollment Status
Pending
Phase
Phase III
Methodist Health System Trial Code
GOG-3035